USHIFU has announced the establishment of India HIFU and the launch of Sonablate(R) HIFU services in Hyderabad, India at Dr. Ramayya’s Pramila Hospital for the treatment of prostate disease. The introduction of the Sonablate(R)500 and the HIFU technology for the treatment of prostate cancer marks a major milestone in the practice of urology in the Indian sub-continent. As the population is aging with a healthy lifestyle it is imperative that patients with prostate cancer are offered a viable alternative to the existing therapy options of surgery and radiotherapy.

According to Millennium Research Group’s (MRG’s) European Markets for Urological Devices 2009 report, the prostate cancer device market-comprising brachytherapy seeds, cryotherapy, and high-intensity focused ultrasound (HIFU) devices-will be driven by earlier detection of prostate cancer due to an increase in screening over the next five years. Screening allows for early detection of cancer, enabling treatment at a curable stage that can be facilitated through minimally invasive devices, such as those required for brachytherapy, cryotherapy, and HIFU procedures.

UroToday.com – Overactive bladder is a key battleground for the pharmaceutical industry and an area of considerable significance to health delivery systems. Given the substantial effects on quality of life, patients are understandably keen for therapeutic strategies which are effective without the significant side effects of anticholinergic drugs. Finally, clinicians have to deal with refractory urinary urgency, which constitutes a significant burden. Published evidence appears to set a confident and positive outlook; a range of effective anticholinergic drugs is available, whilst botulinum toxin is perceived to mop up those who remain bothered despite conservative and medical management.